Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 4;137(2):232–237. doi: 10.1182/blood.2020007081

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by The American Society of Hematology

PMC Copyright notice

Figure 2. — Incidence of mutation, copy loss, structural variation, or high exon 10–spliced transcript of CRBN correlates with outcome to POM in a LEN-refractory cohort. High exon 10–spliced transcript correlates with outcome to induction therapy in ND myeloma. (A) PFS of those who carried the 4 types of CRBN aberration vs those unaffected in the LEN-refractory cohort exposed to POM-based therapy. (B) PFS of those carrying ≥1 of any type of CRBN aberration vs those unaffected in the LEN-refractory cohort exposed to POM-based therapy. (C) Association of high exon 10–spliced CRBN transcript with PFS in the ND cohort undergoing induction therapy. (D) Overall survival (OS) of those carrying ≥1 of any type of CRBN aberration vs those unaffected in the LEN-refractory cohort exposed to POM-based therapy. (E) Association of high exon 10–spliced CRBN transcript with OS in the ND cohort undergoing induction therapy. Comparison of survival curves by log-rank testing in all cases.

Figure 2. — Incidence of mutation, copy loss, structural variation, or high exon 10–spliced transcript of CRBN correlates with outcome to POM in a LEN-refractory cohort. High exon 10–spliced transcript correlates with outcome to induction therapy in ND myeloma. (A) PFS of those who carried the 4 types of CRBN aberration vs those unaffected in the LEN-refractory cohort exposed to POM-based therapy. (B) PFS of those carrying ≥1 of any type of CRBN aberration vs those unaffected in the LEN-refractory cohort exposed to POM-based therapy. (C) Association of high exon 10–spliced CRBN transcript with PFS in the ND cohort undergoing induction therapy. (D) Overall survival (OS) of those carrying ≥1 of any type of CRBN aberration vs those unaffected in the LEN-refractory cohort exposed to POM-based therapy. (E) Association of high exon 10–spliced CRBN transcript with OS in the ND cohort undergoing induction therapy. Comparison of survival curves by log-rank testing in all cases.